Clinical Trial Update: Safety and Efficacy of NNC-0156-0000-0009 in Haemophilia B Patients [Phase 3]

View source ↗

Summary

A Phase 3 trial evaluating the safety and efficacy of NNC-0156-0000-0009 in Hemophilia B completed, with results posted on July 28, 2017.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Hemophilia

Drugs mentioned

• NNC-0156-0000-0009

Snippet

Sponsor: Novo Nordisk A/S | Conditions: Congenital Bleeding Disorder, Haemophilia B | Phase 3 | Status: COMPLETED | Results posted: 2017-07-28